annual CFI:
-$17.77M-$185.77M(-110.58%)Summary
- As of today (July 7, 2025), RARE annual cash flow from investing activities is -$17.77 million, with the most recent change of -$185.77 million (-110.58%) on December 31, 2024.
- During the last 3 years, RARE annual CFI has risen by +$177.60 million (+90.91%).
- RARE annual CFI is now -110.58% below its all-time high of $168.00 million, reached on December 31, 2023.
Performance
RARE Cash from investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFI:
$119.89M+$17.16M(+16.70%)Summary
- As of today (July 7, 2025), RARE quarterly cash flow from investing activities is $119.89 million, with the most recent change of +$17.16 million (+16.70%) on March 31, 2025.
- Over the past year, RARE quarterly CFI has increased by +$25.45 million (+26.96%).
- RARE quarterly CFI is now at all-time high.
Performance
RARE quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFI:
$7.69M+$25.45M(+143.26%)Summary
- As of today (July 7, 2025), RARE TTM cash flow from investing activities is $7.69 million, with the most recent change of +$25.45 million (+143.26%) on March 31, 2025.
- Over the past year, RARE TTM CFI has dropped by -$143.44 million (-94.91%).
- RARE TTM CFI is now -95.42% below its all-time high of $168.00 million, reached on December 31, 2023.
Performance
RARE TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
RARE Cash from investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -110.6% | +27.0% | -94.9% |
| 3 y3 years | +90.9% | +420.9% | +115.3% |
| 5 y5 years | -36.3% | +226.0% | +122.2% |
RARE Cash from investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -110.6% | +93.9% | at high | +143.5% | -95.4% | +102.6% |
| 5 y | 5-year | -110.6% | +93.9% | at high | +143.5% | -95.4% | +102.6% |
| alltime | all time | -110.6% | +93.9% | at high | +143.5% | -95.4% | +102.6% |
RARE Cash from investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $119.89M(+16.7%) | $7.69M(-143.3%) |
| Dec 2024 | -$17.77M(-110.6%) | $102.73M(-137.3%) | -$17.77M(-92.2%) |
| Sep 2024 | - | -$275.50M(-554.9%) | -$227.52M(-302.6%) |
| Jun 2024 | - | $60.56M(-35.9%) | $112.28M(-25.7%) |
| Mar 2024 | - | $94.44M(-188.2%) | $151.13M(-10.0%) |
| Dec 2023 | $168.00M(-157.6%) | -$107.02M(-266.4%) | $168.00M(+62.4%) |
| Sep 2023 | - | $64.30M(-35.3%) | $103.42M(-184.3%) |
| Jun 2023 | - | $99.42M(-10.7%) | -$122.74M(-14.2%) |
| Mar 2023 | - | $111.30M(-164.9%) | -$142.99M(-51.0%) |
| Dec 2022 | -$291.65M(+49.3%) | -$171.60M(+6.0%) | -$291.65M(+471.9%) |
| Sep 2022 | - | -$161.86M(-304.5%) | -$51.00M(-172.7%) |
| Jun 2022 | - | $79.17M(-311.9%) | $70.10M(-239.3%) |
| Mar 2022 | - | -$37.36M(-154.1%) | -$50.31M(-74.2%) |
| Dec 2021 | -$195.37M(+9.1%) | $69.06M(-269.4%) | -$195.37M(+17.3%) |
| Sep 2021 | - | -$40.76M(-1.2%) | -$166.53M(-24.8%) |
| Jun 2021 | - | -$41.25M(-77.4%) | -$221.53M(-16.9%) |
| Mar 2021 | - | -$182.42M(-286.3%) | -$266.42M(+48.7%) |
| Dec 2020 | -$179.12M(+1273.7%) | $97.90M(-202.2%) | -$179.12M(-14.6%) |
| Sep 2020 | - | -$95.76M(+11.2%) | -$209.76M(+504.8%) |
| Jun 2020 | - | -$86.14M(-9.4%) | -$34.68M(+397.5%) |
| Mar 2020 | - | -$95.13M(-241.4%) | -$6.97M(-46.5%) |
| Dec 2019 | -$13.04M(-60.9%) | $67.27M(-15.2%) | -$13.04M(+93.3%) |
| Sep 2019 | - | $79.31M(-235.8%) | -$6.74M(-90.3%) |
| Jun 2019 | - | -$58.43M(-42.3%) | -$69.85M(+10.0%) |
| Mar 2019 | - | -$101.19M(-237.6%) | -$63.50M(+90.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$33.33M(-160.1%) | $73.56M(+353.9%) | -$33.33M(-32.7%) |
| Sep 2018 | - | $16.20M(-131.1%) | -$49.50M(+37.8%) |
| Jun 2018 | - | -$52.07M(-26.7%) | -$35.92M(+629.2%) |
| Mar 2018 | - | -$71.03M(-223.8%) | -$4.93M(-108.9%) |
| Dec 2017 | $55.48M(-39.1%) | $57.39M(+92.7%) | $55.48M(-712.2%) |
| Sep 2017 | - | $29.79M(-241.3%) | -$9.06M(-166.3%) |
| Jun 2017 | - | -$21.08M(+98.5%) | $13.66M(-76.7%) |
| Mar 2017 | - | -$10.62M(+48.5%) | $58.72M(-35.6%) |
| Dec 2016 | $91.12M(-131.2%) | -$7.15M(-113.6%) | $91.12M(+40.8%) |
| Sep 2016 | - | $52.51M(+118.9%) | $64.71M(-149.2%) |
| Jun 2016 | - | $23.99M(+10.2%) | -$131.51M(-50.7%) |
| Mar 2016 | - | $21.77M(-164.9%) | -$266.51M(-8.8%) |
| Dec 2015 | -$292.35M(+136.8%) | -$33.56M(-76.6%) | -$292.35M(+6.0%) |
| Sep 2015 | - | -$143.72M(+29.5%) | -$275.81M(+89.4%) |
| Jun 2015 | - | -$111.01M(+2630.9%) | -$145.64M(+134.5%) |
| Mar 2015 | - | -$4.07M(-76.1%) | -$62.11M(-49.7%) |
| Dec 2014 | -$123.44M(+158.6%) | -$17.02M(+25.7%) | -$123.44M(+29.5%) |
| Sep 2014 | - | -$13.54M(-50.7%) | -$95.31M(+15.5%) |
| Jun 2014 | - | -$27.48M(-58.0%) | -$82.55M(-15.8%) |
| Mar 2014 | - | -$65.40M(-688.5%) | -$98.03M(+105.4%) |
| Dec 2013 | -$47.73M(+3907.9%) | $11.11M(-1512.1%) | -$47.73M(-18.9%) |
| Sep 2013 | - | -$787.00K(-98.2%) | -$58.85M(+1.4%) |
| Jun 2013 | - | -$42.96M(+184.5%) | -$58.06M(+284.5%) |
| Mar 2013 | - | -$15.10M | -$15.10M |
| Dec 2012 | -$1.19M(+28.9%) | - | - |
| Dec 2011 | -$924.00K | - | - |
FAQ
- What is Ultragenyx Pharmaceutical Inc. annual cash flow from investing activities?
- What is the all time high annual CFI for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. annual CFI year-on-year change?
- What is Ultragenyx Pharmaceutical Inc. quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. quarterly CFI year-on-year change?
- What is Ultragenyx Pharmaceutical Inc. TTM cash flow from investing activities?
- What is the all time high TTM CFI for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. TTM CFI year-on-year change?
What is Ultragenyx Pharmaceutical Inc. annual cash flow from investing activities?
The current annual CFI of RARE is -$17.77M
What is the all time high annual CFI for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high annual cash flow from investing activities is $168.00M
What is Ultragenyx Pharmaceutical Inc. annual CFI year-on-year change?
Over the past year, RARE annual cash flow from investing activities has changed by -$185.77M (-110.58%)
What is Ultragenyx Pharmaceutical Inc. quarterly cash flow from investing activities?
The current quarterly CFI of RARE is $119.89M
What is the all time high quarterly CFI for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high quarterly cash flow from investing activities is $119.89M
What is Ultragenyx Pharmaceutical Inc. quarterly CFI year-on-year change?
Over the past year, RARE quarterly cash flow from investing activities has changed by +$25.45M (+26.96%)
What is Ultragenyx Pharmaceutical Inc. TTM cash flow from investing activities?
The current TTM CFI of RARE is $7.69M
What is the all time high TTM CFI for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high TTM cash flow from investing activities is $168.00M
What is Ultragenyx Pharmaceutical Inc. TTM CFI year-on-year change?
Over the past year, RARE TTM cash flow from investing activities has changed by -$143.44M (-94.91%)